Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stergios A Polyzos

Showing results (101-110 of 431) with videos related to

Pageof 44
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|May 14, 2016
Helicobacter pylori-related chronic hepatitis C infection and the risk for cardiovascular diseaseJannis Kountouras, Stergios A Polyzos, Christos Zeglinas, et al.
Endocrine Journal|April 2, 2008
Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatmentAvraam Avramidis, Stergios A Polyzos, Zoe Efstathiadou, et al.
Annals of Gastroenterology|March 16, 2019
Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel diseaseJannis Kountouras, Michael Doulberis, Stergios A Polyzos, et al.
Current Vascular Pharmacology|January 26, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Peripheral Arterial Disease: Associations and Treatment ConsiderationsStergios A Polyzos, Myrsini Orfanidou, Jannis Kountouras, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 1, 2026
Levothyroxine for metabolic dysfunction-associated steatohepatitis: it is the prime time for randomized controlled trialsStergios A Polyzos, Paul M Yen, Leonidas H Duntas
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
A potential impact of Helicobacter pylori-related sarcopenia on severity of portal hypertensionJannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, et al.
Metabolism: Clinical and Experimental|August 6, 2023
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver diseaseStergios A Polyzos, Ilias D Vachliotis, Christos S Mantzoros
Hormones (Athens, Greece)|December 2, 2021
Nonalcoholic fatty liver disease: lifestyle and quality of lifeIlias Vachliotis, Antonis Goulas, Paraskevi Papaioannidou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2019
Influence of Helicobacter pylori-connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high riskJannis Kountouras, Apostolis Papaefthymiou, Michael Doulberis, et al.
Clinics (Sao Paulo, Brazil)|July 27, 2011
The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistanceStergios A Polyzos, Jannis Kountouras, Christos Zavos, et al.
Pageof 44

Showing results (101-110 of 431) with videos related to

Sort By:
Pageof 44
Liver International : Official Journal of the International Association for the Study of the Liver|May 14, 2016
Helicobacter pylori-related chronic hepatitis C infection and the risk for cardiovascular diseaseJannis Kountouras, Stergios A Polyzos, Christos Zeglinas, et al.
Endocrine Journal|April 2, 2008
Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatmentAvraam Avramidis, Stergios A Polyzos, Zoe Efstathiadou, et al.
Annals of Gastroenterology|March 16, 2019
Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel diseaseJannis Kountouras, Michael Doulberis, Stergios A Polyzos, et al.
Current Vascular Pharmacology|January 26, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Peripheral Arterial Disease: Associations and Treatment ConsiderationsStergios A Polyzos, Myrsini Orfanidou, Jannis Kountouras, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 1, 2026
Levothyroxine for metabolic dysfunction-associated steatohepatitis: it is the prime time for randomized controlled trialsStergios A Polyzos, Paul M Yen, Leonidas H Duntas
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
A potential impact of Helicobacter pylori-related sarcopenia on severity of portal hypertensionJannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, et al.
Metabolism: Clinical and Experimental|August 6, 2023
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver diseaseStergios A Polyzos, Ilias D Vachliotis, Christos S Mantzoros
Hormones (Athens, Greece)|December 2, 2021
Nonalcoholic fatty liver disease: lifestyle and quality of lifeIlias Vachliotis, Antonis Goulas, Paraskevi Papaioannidou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2019
Influence of Helicobacter pylori-connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high riskJannis Kountouras, Apostolis Papaefthymiou, Michael Doulberis, et al.
Clinics (Sao Paulo, Brazil)|July 27, 2011
The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistanceStergios A Polyzos, Jannis Kountouras, Christos Zavos, et al.
Pageof 44